Literature DB >> 6678194

Musculoskeletal involvements in female sexual partners of males with Reiter's syndrome.

A H Vilppula, K M Granfors, P E Terho, U I Yli-Kerttula.   

Abstract

To examine the occurrence of signs and symptoms of Reiter's syndrome (RS) in female sexual partners of males with RS we have investigated 43 female consorts of 42 males, originating from 72 consecutive patients suffering from RS or suspicion of RS (SRS). Anamnestic mono-, oligo- or polyarthritis occurred in 14 of the 43 females (32,6%) as compared to 28 out of 311 randomly selected interviewed controls (9,0%). Five of the 43 females had RS and 7 had SRS, (27,9%). However, the diagnosis could have been possible with only anamnestic information in 6 (14%) as compared to 7 out of 311 controls (2,3%). Taking into consideration the 30 males whose sexual partners were not investigated, the theoretically counted values still differ significantly from those of the controls (p less than 0.01). A history of urogenital and, on the other hand, nasopharyngeal or pulmonary infections involvements preceded equally frequently the first or further joint attacks. Evidence of chlamydial infection was found in 53,5% (32/43) of the partners while Yersinia antibodies measured by ELISA occurred with the same frequency as among healthy blood donors. We would like to stress the importance of various infectious involvements, especially sexually transmitted diseases, as etiological agents in joint attacks in females who are sexual partners of males with RS.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6678194     DOI: 10.1007/bf02041553

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  12 in total

1.  Reiter's syndrome: evaluation of proposed criteria.

Authors:  R F Willkens; F C Arnett; T Bitter; A Calin; L Fisher; D K Ford; A E Good; A T Masi
Journal:  Ann Rheum Dis       Date:  1979       Impact factor: 19.103

2.  Incomplete Reiter's syndrome: clinical comparisons with classical triad.

Authors:  F C Arnett
Journal:  Ann Rheum Dis       Date:  1979       Impact factor: 19.103

3.  Acute anterior uveitis after yersinia infection.

Authors:  L Mattila; K Granfors; A Toivanen
Journal:  Br J Ophthalmol       Date:  1982-03       Impact factor: 4.638

Review 4.  Postinfective or reactive arthritis.

Authors:  B Olhagen
Journal:  Scand J Rheumatol       Date:  1980       Impact factor: 3.641

5.  Urogenital involvements in female sexual partners of males with Reiter's syndrome.

Authors:  A H Vilppula; U I Yli-Kerttula; K K Selander; P E Terho
Journal:  Clin Rheumatol       Date:  1983-12       Impact factor: 2.980

6.  Measurement of immunoglobulin M (IgM), IgG, and IgA antibodies against Yersinia enterocolitica by enzyme-linked immunosorbent assay: persistence of serum antibodies during disease.

Authors:  K Granfors
Journal:  J Clin Microbiol       Date:  1979-03       Impact factor: 5.948

7.  Persistence of IgM, IgG, and IgA antibodies to Yersinia in yersinia arthritis.

Authors:  K Granfors; M Viljanen; A Tiilikainen; A Toivanen
Journal:  J Infect Dis       Date:  1980-04       Impact factor: 5.226

8.  Epidemiology of rheumatic diseases in Finland in 1964-76.

Authors:  T Klaukka; K Sievers; J Takala
Journal:  Scand J Rheumatol Suppl       Date:  1982

9.  Chlamydial isolations and serology in Reiter's syndrome.

Authors:  A H Vilppula; U I Yli-Kerttula; A K Ahlroos; P E Terho
Journal:  Scand J Rheumatol       Date:  1981       Impact factor: 3.641

10.  Urogenital involvements and musculoskeletal complaints in women. An interview study and clinical investigation with special reference to chlamydial infections.

Authors:  A H Vilppula; U I Yli-Kerttula; K K Selander; P E Terho
Journal:  Scand J Rheumatol       Date:  1982       Impact factor: 3.641

View more
  1 in total

1.  Reiter's syndrome in male sexual partners of females with Reiter's syndrome or suspicion of it.

Authors:  A H Vilppula; P E Terho; U I Yli-Kerttula
Journal:  Clin Rheumatol       Date:  1983-12       Impact factor: 2.980

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.